<DOC>
	<DOCNO>NCT02722135</DOCNO>
	<brief_summary>This open-label , dose-escalating trial evaluate MTD and/or dose use development evaluation DLT course 1 safety volasertib add standard intensive salvage chemotherapy DNX-FLA paediatric patient AML failure first-line therapy . Furthermore , data efficacy PK/PD volasertib paediatric patient AML add standard intensive salvage chemotherapy collect .</brief_summary>
	<brief_title>A Study Find Safe Dose Volasertib Given Addition Standard Salvage Chemotherapy Children ( Age 3 Months Less Than 18 Years ) With Acute Myeloid Leukaemia , Whom Front-line Chemotherapy Failed</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Inclusion criterion : Patients 3 month &lt; 18 year age time informed consent Patients AML failure frontline intensive AML therapy Lansky score screen &gt; =50 patient 3 month &lt; 12 year Karnofsky score screen &gt; =50 patient 12 &lt; 18 year Use highly effective method birthcontrol , sexually active Parents/legal guardian patient give write informed consent inform assent suitable respective age group Exclusion criterion : Down syndrome Acute promyelocytic leukaemia treatmentrelated AML QTc prolongation LVSF &lt; 30 % Cardiac disease and/or dysfunction Active uncontrolled infection HIV infection , acute chronic hepatitis Inadequate lab parameter Impaired renal function Pregnancy nursing Further exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>